NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer
Stephanie Graff, MD, FACP, FASCO, Brown University, Providence, RI, discusses the latest findings from the NATALEE (NCT03701334) and monarchE (NCT03155997) trials, focusing on the efficacy of ribociclib and abemaciclib in hormone receptor(HR)-positive, HER2-negative advanced breast cancer. Both studies show promising results, with monarchE already leading to abemaciclib’s approval while ribociclib is pending approval. The discussion emphasizes the importance of identifying appropriate patient populations, particularly those at intermediate risk, to optimize long-term outcomes and reduce recurrence rates. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.